Health Related Quality of Life in Patients with Onco-hematological Diseases
- PMID: 32874192
- PMCID: PMC7431682
- DOI: 10.2174/1745017902016010174
Health Related Quality of Life in Patients with Onco-hematological Diseases
Abstract
Background: HRQoL is generally conceptualized as a broad multidimensional construct that refers to patients' perceptions of the impact of disease and its treatment on their physical, psychological, and social functioning and well-being. Little is known in patients with onco-hematological cancer in comparison with the general population and other chronic diseases.
Objective: We assessed HRQoL in patients diagnosed with haematological cancers in comparison with the general population and other chronic diseases.
Methods: The questionnaire Short Form (SF)-12 was administered to 62 patients with onco-hematological disease and results were compared with 702 controls (184 healthy people, 37 Major Depression, 201 Multiple Sclerosis; 23 Wilson disease; 46 Carotidal Atherosclerosis; 60 Celiac disease; 151 solid tumours).
Results: HRQoL in patients diagnosed with a haematological cancer was significantly worse in comparison with the general population (F= 43.853, p <0.00001) but similar when compared with solid tumour and other chronic diseases such as Major Depression and Carotid Atherosclerosis. In addition, HRQoL in patients diagnosed with a haematological cancer was significantly higher than that due to Celiac disease (p <0.00001) and Wilson's disease (p= 0.02), and lower than that due to Multiple Sclerosis (p= 0.032).
Conclusion: This study confirmed that haematological cancers negatively affects overall HRQoL. The results showed an impact of haematological cancers on HRQoL that is similar to what found in patients with solid tumors, Major Depression and Carotid Atherosclerosis. Current successful therapeutic strategy achieved in the treatment of haematological cancers not only positively impact on survival rate but also could improve the overall HRQoL.
Keywords: Celiac disease; HRQoL; Hematological cancer; Mood depression; Multiple Sclerosis; SF-12; Tumors.
© 2020 La Nasa et al.
References
-
- Benvenuti nel sito dell’AIRTUM | Associazione Italiana Registri Tumori. Available from: https://www.registri-tumori.it/cms/
-
- Scalzulli E., Molica M., Alunni F.D., Colafigli G., Rizzo L., Mancini M., Efficace F., Latagliata R., Fo?� R., Breccia M. Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Ann. Hematol. 2019;98(8):1919–1925. doi: 10.1007/s00277-019-03724-9. - DOI - PubMed
-
- Breccia M., Efficace F., Sica S., Abruzzese E., Cedrone M., Turri D., Gobbi M., Carella A.M., Gozzini A., Usala E., Cavazzini F., Danise P., Tiribelli M., Binotto G., Pregno P., Bocchia M., Gaidano G., Crugnola M., Bonifacio M., Avanzini P., Celesti F., Guella A., Martino B., Annunziata M., Luciano L., Stagno F., Vallisa D., Pungolino E., Iurlo A., Rambaldi A., Nardiello I., Orlandi E., Gambacorti-Passerini C., Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk. Res. 2015;39(10):1055–1059. doi: 10.1016/j.leukres.2015.07.004. - DOI - PubMed
-
- Mantovani G., Astara G., Lampis B., Bianchi A., Curreli L., Orr?? W., Carta M.G., Carpiniello B., Contu P., Rudas N. Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different "psychosocial" treatment approaches. A randomized clinical trial. Support. Care Cancer. 1996;4(2):129–140. doi: 10.1007/BF01845762. - DOI - PubMed
LinkOut - more resources
Full Text Sources